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ment of patients with hypertension and chronic kidney disease (CKD).
METHODS The EnligHTN-II study is a post-market clinical investiga-
tion in which patients with uncontrolled hypertension were assigned
to one of three groups; Group A, ofﬁce systolic BP (OSBP) 160 mmHg
and estimated GFR (eGFR) 45 mL/min per 1.73 m2, Group B,
OSBP 140-159 mmHg and eGFR 45 mL/min per 1.73 m2 and Group
C, OSBP 140 mmHg and eGFR 15 mL/min per 1.73 m2. For all three
groups, subjects were required to be on at least 3 anti-hypertensive
medications (including 1 diuretic), or to have documented drug
intolerance such that they are unable to take 3 anti-hypertensive
drugs. Responder analysis was also performed using a 5mmHg
reduction in ambulatory systolic measurement to deﬁne responders.
RESULTS A total of 27 patients with CKD (average age 68.5 (SD 8.2) yrs
taking an average of 5.11 (1.53) anti-hypertensive medications) were
included in this sub-analysis. At baseline, the mean eGFR (mL/min/
1.73m2) was 35.1 (SD 8, range 16 to 43.9). Bilateral renal nerve ablation
was performed using a percutaneous femoral approach. Baseline
average OSBP was 169 (20.2) mmHg, average ODBP was 85.4
(13.9) mmHg, average ambulatory SBP (ASBP) was 106.2 (18.2) mmHg,
and average ambulatory DBP (ADBP) was 82.2 (14.9) mmHg. At present
24 6-month and 17 12-month follow-up visits are completed. The
average reduction in OSBP/ODBP was 9.0 (25.8)/8.1 (10.3) mmHg
(p¼ns/<0.0018) and 9.8 (25.6)/8.5 (16.3) mmHg (p¼ns/0.0465) at 6 and
12M follow up respectively. The average reduction in ASBP/ADBP was
9.0 (24.1)/6.1 (12.5) mmHg (p¼ns/0.0281) and 14.7 (24.5)/8.1
(14.1) mmHg (p¼ns for both) at 6 and 12 month follow up respectively.
Changes in eGFR, serum creatinine, and urine albumin to creatinine
ratio were not statistically different from baseline at either 6 or 12M
follow up. The following baseline factors were associated with the
responder group at the 90% conﬁdence level: less sleep apnea, higher
eGFR, lower serum creatinine, higher ofﬁce diastolic pressure, higher
systolic & diastolic ambulatory pressures, and less isolated systolic
hypertension.
CONCLUSIONS In this challenging cohort with uncontrolled hyper-
tension and chronic kidney disease, multi-electrode renal denervation
appears to be safe and results in durable reduction in daytime ofﬁce
and ambulatory BP which was signiﬁcant at 6 months follow up.
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BACKGROUND Renal denervation remains a promising treatment
option for uncontrolled hypertension. The Peregrine System Infu-
sion Catheter is a site-speciﬁc delivery catheter, with 3 micro-needles
that can deliver therapeutic agents directly into the perivascular
(adventitial) space. The infusion of micro-volumes of alcohol, a potent
neurolytic agent, into the perivascular space of the renal artery pro-
vides a means to precisely target the peri-renal sympathetic nerves
and to perform “chemical” renal denervation. This approach has been
demonstrated to be safe and effective in preclinical studies. A First-In-
Human study was conducted to evaluate the safety and performance
of the Peregrine System for perivascular “chemical” denervation.
METHODS This was a prospective, single center study to treat pa-
tients with medication-resistant hypertension (n¼18), with follow-up
through 6 months. Subjects were treated with an infusion of 0.3 mL
dehydrated alcohol injection USP (98%) to each renal artery using the
Peregrine System. Primary device success was deﬁned as successful
alcohol delivery, without complications. Angiograms were read by an
independent core laboratory. The primary (safety) endpoints were:
complications associated with catheter insertion and delivery of the
neurolytic agent, and/or serious vascular access complications. The
secondary endpoint was a reduction in ofﬁce blood pressure (OBP) at
6 months, compared to baseline values.RESULTS The ﬁrst 5 subjects were staged, with unilateral treatment
followed by the treatment of the contralateral renal artery 4 weeks
later. There were no procedural complications, adverse events or any
device malfunction in any subject (23 procedures). Average procedure
time was 10 min (range 2 to 21 min). There were no acute or long term
vascular events, with no angiographic evidence of any renal artery
stenosis at 6-months (n¼ 32 arteries). One subject died 9 weeks post-
procedure due to a mesenteric artery occlusion, which was deter-
mined by the Investigator and an Independent Medical Monitor to be
unrelated to the device or the procedure. No other serious adverse
events were reported. One subject was lost to follow-up. At 6 months
14/16 (88%) had a reduction in systolic OBP. The mean ofﬁce SBP was
reduced from 175  17 mm Hg to 151  26 mm Hg, and mean ofﬁce DBP
was reduced from 95  17 mm Hg to 83  10 mm Hg. Controlling
antihypertensive medications in this trial was challenging, however,
data was collected from 12/16 subjects. Overall, there was a BP
reduction despite decreased use of antihypertensive medications
(mean reduction of 1.3  0.4 medications per patient).
CONCLUSIONS The use of alcohol with the Peregrine System for
“chemical” renal denervation appears to be safe and effective in this
First-In-Human study. Additional clinical trials are ongoing and
planned to more completely assess the use of this device in a larger
cohort of patients.
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BACKGROUND Non-invasive ablation via radiosurgery has excelled in
the treatment of tumors and recently in the therapy of cardiac ar-
rhythmias. Precision of image contouring and beam delivery, along
with motion compensation have been developed. A recent pre-clinical
study has evaluated the feasibility of such approach to ablate targets
associated with renal nerve hypertension, such as aortic-renal ganglia
and their attendant renal nerves. Much as in cardiac arrhythmia
ablation, this painless, non-invasive, outpatient approach can be
attractive.
METHODS Six Hanford mini-swine (under appropriate USDA, AALAC
control) underwent CT angiography to identify kidneys and renal ar-
teries, under general anesthesia. A radiosurgical plan was constructed
for the ablation of the renal ganglia bilaterally, and for the ablation of
the renal nerves proximal to renal artery adventitia for 50% of its
circumference. Treatment was accomplished using the cyberknife,
under Multiplan treatment planning guidance. Dose administered to
the targets was 50Gy in a single treatment session. Animals were
followed to 6 months and then the organs of interest were harvested.
Pathology(micro and gross) was performed on the organs submitted,
emphasizing the renal arteries, aorta and kidneys bilaterally to
examine for renal artery or kidney injury, and to look for renal nerve
ﬁbrotic change at the target. Tyrosine hydroxylase staining was per-
formed on renal nerve tissue and ganglia bilaterally. Norepinephrine
levels were monitored (tissue-kidney, and blood) during the animal’s
life. Radiosurgery treatment plans were conformal, and dose was
minimized to surrounding structures, such as kidney, aorta, and renal
artery, as much as possible. Treatment planning was conservative,
such that a complication was calculated based on dose to structures
was estimated to be less than a 5% chance.
RESULTS There were no treatment related adverse events. All ani-
mals survived to treatment endpoint. Gross pathology failed to revel
any radiation change. Pathology of the renal arteries bilaterally
showed minimal to any evidence of renal arterial change and there
was no evidence of renal artery stenosis. Norepinephrine levels across
all animals at the 6 month time point showed a decline of 64% from
baseline levels just prior to treatment. Fibrosis was observed in renal
nerve tissue identiﬁed in arterial tissue staining. Tyrosine hydroxy-
lase staining of renal nerve tissue showed appropriate change
consistent with decrease in enzymatic availability.
CONCLUSIONS Non-invasive radiosurgery has the potential to offer
and outpatient painless option to ablate neural tissue contributing to
refractory hypertension. Software has been developed (3-D) to allow
the clinician to target precisely, in consideration of motion and nearby
structures, safely. Given that these ablation lesions are homogeneous
